Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing ...

Abdullah also attributed GSK’s willingness to go all-in on mo-rez on the leadership of Luke Miels, who stepped up as CEO of ...

With the caveat that cross-trial comparisons can be unreliable, zasocitinib appears to have an advantage over Sotyktu. BMS reported PASI 90 rates of 32% to 42% and PASI 100 rates of 10% to 14% in its ...

Alkermes announced today the initiation of the Brilliance Studies, a phase 3 program that will test the safety and efficacy ...

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...

Phase three of the $130 million Michigan Department of Transportation project is set to begin Monday, March 30, and will continue through November.